Literature DB >> 34513284

Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUVmax in PET scan.

Amin Haghighat Jahromi1,2, Matthew Zabel1, Ryosuke Okamura3, Carl K Hoh1, Razelle Kurzrock3.   

Abstract

The relationship between higher variant allele fraction (VAF) of genomic alterations in circulating tumor DNA (%ctDNA), an indicator of poor outcome, and maximum standardized uptake value (SUVmax), the most commonly used semi-quantitative parameter in 18F-FDG PET/CT, has not been studied. Overall, 433 cancer patients had blood-based next generation sequencing. Maximum and sum of %ctDNA alterations (%ctDNAmax and %ctDNAsum, respectively) represent the maximum and sum of VAF, reported as a percentage. The subset of 46 eligible patients had treatment-naïve metastatic disease and PET/CT imaging, with median 13 days prior to ctDNA testing. We found a linear correlation between the maximum VAF (%ctDNAmax) (as well as the sum of the VAFs (%ctDNAsum)) and SUVmax of the most 18F-FDG-avid lesion (r=0.43, P=0.003; r=0.43, P=0.002; respectively). Our data suggest that SUVmax may be a non-invasive and readily available surrogate indicator for %ctDNA, a prognostic factor for patient survival. Since higher %ctDNA has been previously correlated with worse outcome, the relationship between SUVmax, %ctDNA and survival warrants further study. AJNMMI
Copyright © 2021.

Entities:  

Keywords:  Genomic alterations; PET/CT; SUVmax; Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA); cancer; circulating tumor DNA (ctDNA)

Year:  2021        PMID: 34513284      PMCID: PMC8414395     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  23 in total

1.  Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules.

Authors:  Amin Haghighat Jahromi; Farshad Moradi; Carl K Hoh
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

Review 2.  Circulating Tumor DNA: Measurement and Clinical Utility.

Authors:  Joshua Donaldson; Ben Ho Park
Journal:  Annu Rev Med       Date:  2017-08-28       Impact factor: 13.739

3.  Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients.

Authors:  Amin Haghighat Jahromi; Geraldine Chang; Razelle Kurzrock; Carl K Hoh
Journal:  Cancer Biol Ther       Date:  2020-11-01       Impact factor: 4.742

Review 4.  Molecular profiling and the reclassification of cancer: divide and conquer.

Authors:  Javier Munoz; Charles Swanton; Razelle Kurzrock
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

Review 5.  From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.

Authors:  Jacob J Adashek; Vivek Subbiah; Razelle Kurzrock
Journal:  Trends Cancer       Date:  2020-09-29

6.  Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.

Authors:  Joel M Baumgartner; Paul Riviere; Richard B Lanman; Kaitlyn J Kelly; Jula Veerapong; Andrew M Lowy; Razelle Kurzrock
Journal:  Ann Surg Oncol       Date:  2020-08-06       Impact factor: 5.344

Review 7.  Emerging concepts in liquid biopsies.

Authors:  Samantha Perakis; Michael R Speicher
Journal:  BMC Med       Date:  2017-04-06       Impact factor: 8.775

Review 8.  Bringing radiomics into a multi-omics framework for a comprehensive genotype-phenotype characterization of oncological diseases.

Authors:  Mario Zanfardino; Monica Franzese; Katia Pane; Carlo Cavaliere; Serena Monti; Giuseppina Esposito; Marco Salvatore; Marco Aiello
Journal:  J Transl Med       Date:  2019-10-07       Impact factor: 5.531

Review 9.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

10.  Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients.

Authors:  Amin Haghighat Jahromi; Donald A Barkauskas; Matthew Zabel; Aaron M Goodman; Garret Frampton; Mina Nikanjam; Carl K Hoh; Razelle Kurzrock
Journal:  EJNMMI Res       Date:  2020-12-09       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.